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Post-cardiac arrest myocardial dysfunction (PCAMD) is a frequent complication faced during post-
resuscitation care that adversely impacts survival and neurological outcome. Both mechanical and 
electrical factors contribute to the occurrence of PCAMD. Pre-arrest ventricular function, the cause 
of cardiac arrest, global ischaemia, resuscitation factors, ischaemia/reperfusion injury and post-
resuscitation treatments contribute to the severity of PCMAD. The pathophysiology of PCAMD is 
complex and include myocytes energy failure, impaired contractility, cardiac oedema, 
mitochondrial damage, activation of inflammatory pathways and the coagulation cascade, persistent 
ischaemic injury and myocardial stiffness.  
Hypotension and low cardiac output with vasopressor/inotropes need are frequent after 
resuscitation. However, clinical, hemodynamic and laboratory signs of shock are frequently altered 
by cardiac arrest pathophysiology and post-resuscitation treatment, potentially being misleading and 
not fully reflecting the severity of post-cardiac arrest syndrome. Even if validated criteria are 
lacking, an extensive haemodynamic evaluation is useful to define a “benign” and a “malign” form 
of myocardial dysfunction and circulatory shock, potentially having treatment and prognostic 
implications. Cardiac output is frequently decreased after cardiac arrest, particularly in patients 
treated with target temperature management (TTM); however, it’s not independently associated 
with outcome. Sinus bradycardia during TTM seems independently associated with survival and 
good neurological outcome, representing a promising prognostic indicator. Higher mean arterial 
pressure (MAP) seems to be associated with improved survival and cerebral function after cardiac 
arrest; however, two recent randomized clinical trials failed to replicate these results. 
Recommendations on haemodynamic optimization are relatively poor and are largely based on 
general principle of intensive care medicine. 
 









Cardiac arrest (CA) is a leading cause of death in Europe and has an incidence of 84.0–88.6 cases 
per 100,000 adults every year, with survival rates of only 8–10% and few with good neurological 
outcomes.1,2 Despite significant improvements in resuscitation and post-resuscitation care, CA 
survival has only slightly increased.3 About half of the patients admitted alive in hospital die before 
discharge, and even fewer show good long-term neurological outcomes.4 Poor prognosis is due to 
post-CA syndrome (PCAS), a pathophysiological state that includes post-CA myocardial 
dysfunction (PCAMD) and cerebral injury and is related to the whole-body ischaemia-reperfusion 
(I/R) injury.4 
 
PCAMD is a complex condition where pre-arrest ventricular function, the cause of CA, global 
ischaemia, resuscitation factors, I/R injury and post-CA treatments contribute to the severity of 
myocardial injury and cardiac dysfunction.4–7 Haemodynamic instability requiring 
pharmacological/mechanical support occurs in two thirds of CA patients with ventricular 
fibrillation.8 If not promptly recognized and treated, this clinical condition can deteriorate, causing 
multiorgan dysfunction and early death.4,9,10 In patients that survive to hospital discharge, poor 
cerebral perfusion and ischaemia during intensive care unit stay exacerbates the neurological 
injury.4 
 
The mechanisms of PCAMD overlap with those observed in other clinical syndromes, such as 
myocardial infarction, sepsis-induced cardiomyopathy and stress-related cardiomyopathy (i.e. 
Tako-Tsubo syndrome), and after cardiopulmonary bypass. Nonetheless, PCAMD has a typical 
time course and features that need to be considered in order to provide comprehensive care.4,6,7 
 
Pathophysiology of myocardial dysfunction after CA 
PCAMD is defined as a reversible deterioration of cardiac performance that occurs after return of 
spontaneous circulation (ROSC), not fully explained by myocardial ischaemia or persistent 
coronary occlusion. As opposed to the regional distribution of myocardial wall dyskinesis in acute 
myocardial infarction, PCAMD impacts the heart globally. Both mechanical and electrical factors 
contribute to the occurrence of PCAMD; typical features include severe impairment in systolic and 
diastolic function and cardiac dysrhythmias and recurrent CA.11 PCAMD overlaps with pre-arrest 
cardiac performance and myocytes necrosis, due to coronary ischaemia and I/R injury, so it is 
particularly tricky to accurately distinguish between reversible and irreversible myocardial injury. 
 
Cardiac arrest 
Decrease in oxygen delivery shifts cellular metabolism to non-oxidative glycolysis, decreasing ATP 
production and causing intracellular acidosis and sodium imbalance due to Na+/K+ ATPase 
inhibition; furthermore, accumulated H+ activates the sarcolemmal sodium-hydrogen exchanger 
isoform-1, worsening Na+ overloads.12 Increase in cytosolic sodium causes cell swelling and 
promotes intracellular Ca2+ influx through Na+/Ca2+ exchangers; ATP deficit impairs the activity of 
both plasma membrane calcium ATPase and sarco-/endoplasmatic reticulum calcium ATPase, 
further exacerbating Ca2+ overload. Calcium overload promotes apoptosis by caspases activation, 
activates intracellular proteases/phospholipases and initiates the formation of the mitochondrial 
permeability transition pore. Global hypoperfusion and ischaemia trigger a whole-body 
inflammatory response, aggravating mitochondrial injury, damaging membrane phospholipids and 
impairing fatty acid metabolism. Finally, endothelial damage and initiation of the coagulation 
cascade occur, causing neutrophil and platelet adhesion and microthrombi formation in peripheral 
microcirculation. 
 
During cardiopulmonary resuscitation 
Chest compression efficacy is intrinsically limited, and the resulting heart perfusion is not enough 
to revert cardiac ischaemia. Cardiac stiffening caused by prolonged ischaemia (i.e. “stone heart”) 
and by progressive dilatation of the ventricles during CPR13 impairs the blood flow generated 
during chest compressions. Microthrombosis and leucocyte adhesion will further impede 
myocardial reperfusion (i.e. “no-reflow phenomenon”).14 High levels of circulating adrenaline bind 
with β-2 receptors, coupled with inhibitory G proteins, and decrease contractility;15 furthermore, 
catecholamines cause microvascular coronary vasoconstriction, increase oxygen consumption and 
exacerbate oxidative stress, intensifying the severity of PCAMD.16 Cardiac defibrillation 
contributes to myocardial injury proportional to the energy and the number of shocks delivered.17,18 
 
After return of spontaneous circulation 
The detrimental effects initiated during CA continue after ROSC, particularly in the first hours after 
resuscitation. Indeed, the restoration of tissue perfusion initially paradoxically aggravates the I/R 
injury due to overproduction of reactive oxygen species (ROS), further impairing beta-adrenergic 
signalling and ATP production in the heart. Cytokines released have direct negative inotropic 
effects and intensify cellular energy failure and ROS production.19 Glycolysis is persistently 
uncoupled from oxidative phosphorylation, worsening intracellular acidosis and impairing myocyte 
contractile function. Persistently high levels of intracellular Ca2+ and circulating catecholamines 
aggravate the potential for cardiac dysrhythmia and recurrent CA. Cell metabolism starts to improve 
3–6 hours after ROSC, due to enhanced ATP and antioxidant production. Ion pumps and cellular 
enzymes increase their functionality, restoring intracellular Na+ and Ca2+ normal concentrations. 
The fading of the “no-reflow” phenomenon, the catabolism of circulating catecholamines and a 
decrease in H+ concentration increase the sensitivity of contractile proteins to Ca2+ and ameliorate 
cardiac contractility. Generally, the alterations associated with PCAMD resolve in the next 24–72 
hours, even if longer recovery has been reported.20 
 
Cardiac and haemodynamic characteristics after CA 
After CA, patients frequently exhibit various degrees of haemodynamic instability and hypotension, 
requiring advanced haemodynamic monitoring, aggressive fluid replacement, vasopressor/inotropic 
drugs and, in selected cases, mechanical support of the circulation.7,11,21 As in other clinical 
conditions, haemodynamic optimization has become a cornerstone of post-resuscitation care;22 
however, the level of evidence is scarce, and the impact on the outcome is unclear,23–25 representing 
a relevant knowledge gap in resuscitation science.26 
 
Soon after resuscitation, the heart rate and arterial pressure are elevated, due to high concentrations 
of endogenous and exogenous catecholamines. The heart shows signs of both diastolic dysfunction 
(cardiac oedema, ischaemic contracture and impaired relaxation) and systolic dysfunction (impaired 
contractility, inadequate oxygen delivery, intracellular acid-base and ion imbalance); as a result, 
cardiac output is generally decreased and patients may manifest with hypotension, low cardiac 
output and poor tissue perfusion (i.e. cardiogenic shock).27 Moreover, distributive shock may 
overlap with cardiogenic shock, due to superimposed vasodilation secondary to I/R injury and 
systemic inflammation, requiring volume expansion and prolonged vasopressor support.4,9 
 
Defining cardiogenic shock in the post-cardiac arrest patient 
A clear impediment for the research of cardiac dysfunction after CA is the lack of well validated 
criteria to define cardiogenic shock. Criteria such as hypotension (i.e. systolic blood pressure < 90 
mmHg, or vasopressors required to achieve a blood pressure ≥ 90 mmHg), signs of impaired organ 
perfusion (e.g. central nervous system abnormalities including confusion, lack of alertness or loss of 
consciousness; oliguria; cold, clammy skin and extremities; increased arterial lactate > 2 mmol l-1) 
in the state of normo- or hypervolaemia and reduced cardiac index (CI, i.e. < 1.8 or < 2.2 l min-1 m-2 
with cardiac support) or elevated left ventricular filling pressures (i.e. pulmonary capillary wedge 
pressure > 15 mmHg) are not useful.28 Indeed, all CA patients have high blood lactate at admission 
to the hospital, and patients receive target temperature management (TTM), resulting in cool 
extremities, skin mottling and hypothermic diuresis. In addition, patients receive sedative and 
neuromuscular-blocking agents, which makes neurological evaluation impossible. Lactate may also 
be a poor indicator of tissue oxygenation in post-CA patients, since gut ischaemia and seizures may 
increase serum lactate levels, and hypothermia may reduce lactate clearance by the liver.29 
 
General criteria for adequate perfusion include lactate clearance and adequate diuresis.22 However, 
normal serum lactate levels do not guarantee optimal brain oxygenation. Therefore, low cardiac 
output is easily undetected if advanced haemodynamic monitoring is not used.8 
 
Cardiac output 
Low cardiac output is present in up to two thirds of CA patients,8,9 particularly in those with a 
cardiac cause of the CA.8,30 Some studies indicate that it accounts for most of the early death in the 
ICU in the first three days.10 Typically, the patients are in cardiogenic shock and suffer from low 
diastolic pressure, causing coronary hypoperfusion with a progressive lowering of cardiac output, 
ultimately resulting in multiple organ failure, refractory shock and death.5,9 It has been reported that 
cardiac output remains depressed for 8 h after ROSC and progressively recovers in the next 24–
48 h, demonstrating the reversible nature of PCAMD in patients without large acute myocardial 
infarction (AMI) as the precipitating cause of CA.9 These data are consistent with numerous 
experimental reports.31–33 Patients with pre-existing cardiac dysfunction have lower post-
resuscitation echocardiographic left ventricular ejection fraction (LVEF) and cardiac output 
compared to the healthy population; however, the relative decline in LVEF from baseline values is 
similar in both patient groups.34 Adequate measurement of cardiac output by continuous 
thermodilution may be challenging when intravascular cooling devices are used, and continuous 
mixed venous oxygen (SvO2) saturation may better reflect the cellular oxygen balance.35 Various 
studies have questioned the impact of cardiac output on resuscitation outcomes. In a subgroup 
analysis from the TTM trial, cardiac index during TTM after CA was not associated with mortality 
or cause of death (cerebral vs. non-neurological) regardless of the level of the TTM target 
temperature (Table I).36 Nonetheless, haemodynamic profiles of patients dying from non-
neurological death significantly differed compared to survivors and cerebral deaths, showing that 
reduced mean arterial pressure and elevated lactate were independent predictors of non-neurological 
mortality. Even if the cardiac index was not a mortality predictor by itself, the presence of CI < 2.5 l 
min-1 m-2 and blood lactate > 2 mmol l-1 identified patients with higher mortality. Similarly, cardiac 
output failed to predict the incidence of acute kidney failure and the need for renal replacement 
therapy, whereas heart rate, lactate levels and mean arterial pressure were better predictors (Table 
I).37 
 
Post-resuscitation care (including hypothermia, sedation, analgesia, paralysis and mechanical 
ventilation) may affect cardiac output independently of the extent of myocardial injury and 
PCAMD. Indeed, patients treated with TTM (deeply sedated and frequently paralyzed) reduce 
cellular metabolism and oxygen consumption, so even low cardiac output may guarantee adequate 
oxygen delivery. Moreover, superimposed vasodilation may deceptively increase cardiac output 
without any improvement in tissue perfusion.4,9 In fact, a preserved or augmented CI does not 
exclude the presence of extensive microcirculatory alterations, resulting in regional hypoperfusion 
and organ dysfunction.27 
 
Heart rate 
Heart rate has been associated with outcome in CA patients; somewhat surprisingly, sinus 
bradycardia during TTM has been shown to be associated with lower mortality and less severe 
organ dysfunction (Table I).38,39 Moreover, lower time-weighted mean heart rates at 48- and 72-
hours post-resuscitation were associated with improved one-year neurological outcomes, even if the 
relationship was less marked in TTM patients.40 Hypothermia can modify the heart rate through 
various mechanisms; after an initial phase of tachycardia, the heart rate progressively decreases, due 
to alterations in the spontaneous depolarization of cardiac pacemaker cells, in the conduction of 
myocardial impulses, in the duration of action potentials and in autonomic nervous system function 
during the maintenance phase of TTM. Moreover, by reducing oxygen consumption, a decrease in 
oxygen delivery is relatively well tolerated. Sinus bradycardia probably represents a marker of 
preserved autonomic response, and the lack of this reflex could identify patients with more severe 
PCAS and greater neurological injury.39,40 The crosstalk between heart rate and autonomic function 
(e.g. the heart rate variability41 and the haemodynamic response during different phases of 
hypothermia42) is a topic of growing interest. No prospective trial has evaluated potential strategies 
to reduce heart rate during post-resuscitation care, so it is unclear if lower heart rate represents a 
prognostic marker or could be a future treatment target. Interestingly, a right bundle branch block 
recording in the first ECG at hospital admission was directly associated with higher mortality and 
was independently associated with an unfavourable prognosis;43 however, further investigations are 
needed to confirm these results. 
 
Arterial pressure 
Mean arterial pressure (MAP) has been widely investigated as a potential haemodynamic goal in 
post-resuscitation care, and various studies reported a positive association between MAP and 
outcome (Table I).44-46 Furthermore, MAP < 65–70 mmHg and higher doses of vasopressor were 
associated with increased incidence of organ dysfunction (e.g. acute kidney injury), mortality and a 
poor neurological outcome.45,47–50 Two prospective randomized clinical trials (COMACARE51 and 
Neuroprotect post-CA52 trials; Table I) compared the impact of higher MAP (80–100 mmHg and 
85–100 mmHg with SvO2 65–75%) with low-normal MAP values (65–75 mmHg and 65 mmHg, 
respectively); in both studies, a haemodynamic strategy with higher MAP was feasible and safe; 
however, no improvements in neurological outcome were observed at 180 days.51,52 However, 
higher MAP was associated with lower plasma cardiac troponin T levels when data from both 
studies were merged, suggesting that a balanced use of α-1 vasoconstrictor could increase coronary 
perfusion pressure and ameliorate myocardial ischaemia without significant side effects (personal 
communication from Pekka Jakkula). 
 
Targeting higher MAP values has a pathophysiological rationale, particularly in the immediate 
hours after resuscitation. Cerebral perfusion is severely impaired, due to intracerebral 
vasoconstriction, high circulating catecholamines, persistent vascular occlusion, a right-shift of 
cerebral autoregulation limits and a heterogeneous distribution of blood flow;14,53,54 concordantly, a 
higher MAP should better preserve cerebral blood flow. However, the evidence is limited regarding 
this hypothesis. Even if no target arterial pressure can be recommended, a MAP > 65–70 mmHg 
seems reasonably safe and consistent with similar recommendations in critical care. Possibly, a 
fixed MAP value simply does not fit every patient need, and a personalized approach based on 
individual comorbidities and physiological response should be encouraged.50–52 
 
Practical considerations 
Cardiac output by itself may not be the best indicator to identify patients with increased risk of 
mortality and poor long-term neurological function. However, when cardiac function is 
contextualized with other clinical, haemodynamic and laboratory variables, two distinct 
haemodynamic phenotypes could be observed in patients with low cardiac output at admission: a 
“benign” and a “malign” form of myocardial dysfunction and cardiogenic shock (Table II). It is 
important to recognize these two different patterns, because they potentially have treatment and 
prognostic implications (Figure 1). 
 
Recommendations on haemodynamic optimization are relatively poor and are largely based on 
general principle.22 An echocardiogram should be obtained as early as possible, ideally on 
admission; serial echocardiographic evaluation allows continuous monitoring and treatment 
titration. Cerebral tissue oxygen saturation as measured with near infrared spectroscopy did not 
show a good correlation with prognosis. In the absence of good indicators of adequate cerebral and 
vital organ oxygenation, treatment should be guided by haemodynamic variables (e.g. blood 
pressure, heart rate, urine output, rate of lactate clearance and central venous oxygen saturation), 
taking into consideration their specific limitations, as previously discussed. In intensive care, an 
arterial line for continuous blood pressure monitoring is essential, and a central venous access is 
also indispensable for blood sampling, blood gas analysis and drug administration. Advanced 
cardiac output monitoring should be considered in patients with a malign form of cardiogenic 
shock, and the choice of a specific device/technology should be based on local availability and 
expertise. 
 
The best treatment strategy to optimize cardiac function is still debated. Faster lactate clearance and 
improved outcomes were observed when a higher MAP was achieved using fluid over 
vasopressors.55 Even if it is not possible to exclude that this is feasible in less severely injured 
patients, abundant fluid resuscitation in the first hours after resuscitation is frequent and remarkably 
well tolerated.9,23 Vasopressors are used to target MAP and limit positive fluid balance. No specific 
drug demonstrated a clear advantage; however, the use of adrenaline is likely best avoided. In a 
recent randomized controlled pilot trial, the use of adrenaline compared to noradrenaline in AMI 
patients resulted in more tachycardia, refractory cardiogenic shock, multiple organ dysfunction and 
mortality, probably due to catecholamine overload and stress cardiomyopathy.15,56,57 Currently, 
noradrenaline is the first-line vasopressor to maintain target MAP. One should, however, be careful 
using unopposed α-1 induced vasoconstriction, since elevated afterload may impair stroke volume, 
cardiac output and cerebral perfusion. A combined approach using vasopressors and inotropes, as 
guided by continuous SvO2 measurements, has been tested in the Neuroprotect post-CA trial and 
resulted in clear improvements in cerebral perfusion and oxygenation during the first 12 hours of 
ICU stay.52 Other inotropes have been proposed (e.g. levosimendan, PDE-III inhibitors) and 
represent valid alternatives in selected patients.11 Mechanical circulatory support (e.g. intra-aortic 
balloon pump, percutaneous ventricular assist device and extracorporeal life support) should be 
promptly inserted in selected patients when pharmacological therapies fail.21,58 
 
Fast-track coronary angiography (CAG) and percutaneous coronary intervention (PCI) are indicated 
for patients presenting ST-segment-elevated myocardial infarction (STEMI) on post-resuscitation 
ECG.59,60 Early reperfusion is associated with improved survival and good neurological outcomes.61 
In patients without STEMI, non-coronary causes of CA should be excluded.59,60 If alternative 
causes are not identified, delayed CAG and PCI are indicated, ideally within two hours, since an 
acute critical coronary occlusion could be identified in up to one third of the patients.61 The role of 
CAG and PCI in this group of patients is less well established, and recent evidence does not support 





 Post-cardiac arrest myocardial dysfunction frequently complicates post-resuscitation care 
and adversely impacts survival and neurological outcome. 
 Clinical criteria to define cardiogenic shock are not validated in cardiac arrest population; 
indeed, low cardiac output is frequent and not independently associated with mortality or 
adverse outcome. 
 Two distinct haemodynamic phenotypes could be observed in patients with PCAMD and 
low cardiac output at admission: a “benign” and a “malign” form of myocardial dysfunction 
and cardiogenic shock. 
 Evidence on best treatment strategy for haemodynamic optimization after cardiac arrest is 
scarce; actual recommendations are largely based on general principles of haemodynamic 
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TITLES OF FIGURES 









Randomized clinical trial, 
n=123  
Comatose, ventilated, adult patients 
resuscitated from VF/pVT OHCA 
Confirmed or suspected cardiac 
cause 
ROSC within 10-45 min from OHCA 
Low-normal (65-75 mmHg) vs. 
high-normal (80-100 mmHg) MAP  
Targeting a specific range of MAP is feasible. These MAP 
range are safe. No improvements in NSE after 48 hours 





Randomized clinical trial, 
n=112 
Comatose, adult patients resuscitated 
from OHCA of resumed cardiac 
cause 
Sustained ROSC for >20 min 
EGDHO (MAP 85-100 mmHg, 
SvO2 65-75%) vs. MAP 65 mmHg 
EGDHO was safe, improved cerebral oxygenation 
measured by NIRS, but did not result in an improvement in 
neurological outcome 
     
OBSERVATIONAL STUDIES 
Study Design and patients included  Inclusion criteria Main results 
Kilgannon et al.
45  Prospective observational 
study, n=151 
Comatose, adult patients resuscitated 
from IHCA and OHCA 
Time-weighted average MAP pressure was associated with good neurologic outcome at a MAP 
threshold greater than 70 mmHg 
Oksanen et al.
40 Preplanned sub-study of the 
FINNRESUSCI study, n=504 
Adults patients resuscitated from 
OHCA 
Lower heart rate was independently associated with one-year good neurological outcome 
Thomsen et al.
39
  Retrospective study, n=234 Comatose, adult patients resuscitated 
from OHCA of presumed cardiac 
cause 
Sustained ROSC for >20 min 
Synus bradycardia (HR < 50 bpm) during TTM at 33°C was independently associated with lower 
180-day mortality rate  
Grand et al.
36 Post-hoc analysis of the TTM 
trial, n=151 
Comatose, adult patients resuscitated 
from OHCA of presumed cardiac 
cause 
Sustained ROSC for >20 min 
Cardiac output was not an associated with mortality, independently from the presumed cause of 
death. If lactate is normal, low cardiac index during TTM seems benign and not associated with 
mortality 
Grand et al.
37 Post-hoc analysis of the TTM 
trial, n=152 
Comatose, adult patients resuscitated 
from OHCA of presumed cardiac 
cause 
Sustained ROSC for >20 min 
Cardiac output is not an independent predictor of AKI 
Heart rate, MAP and lactate were independently associated with AKI 
Table I. Relevant recent literature on post-resuscitation cardiac function 
AKI: acute kidney injury; CA: cardiac arrest; EGDHO: early goal-directed haemodynamic optimization; IHCA: in-hospital cardiac arrest; OHCA: out-of-hospital cardiac arrest; MAP: mean arterial 
pressure; NIRS: near infra-red spectroscopy; NSE: neural serum enolase; pVT: pulseless ventricular tachycardia; ROSC: return of spontaneous circulation; TTM: target temperature management; VF: 
ventricular fibrillation. 
 
  BENIGN MALIGN 
Arterial pressure MAP > 65-70 mmHg 
No/moderate vasopressor support 
MAP < 60-65 mmHg 
High dosage of vasopressor for prolonged time 
Heart rate and cardiac 
rhythm 
Sinus bradycardia during TTM 
Increase after rewarming within 
physiological limits 
Constantly elevated 
No significant changes during the various phases of TTM 
Various degree of dysrhythmia (e.g. rapid atrial fibrillation, sustained 
ventricular ectopy, ventricular tachycardia, recurrent CA) 
Cardiac output Recovery in the first 3 days after admission Progressive decrease 
Need for mechanical circulatory support 
Diuresis > 0.5 ml kg-1 h-1 < 0.5 ml kg-1 h-1 
Need for renal replacement therapy 
Lactate Constant clearance 
Decrease to low/normal value within 6-12 
hours 
Slow clearance 
Elevated for several days 
Central/mixed venous 
saturation 









Table II. Proposed phenotypes of cardiogenic shock in patients resuscitated from cardiac arrest 
CA: cardiac arrest; MAP: mean arterial pressure; TTM: target temperature management. 
 
